Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
Tentarix Biotherapeutics has raised $35.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
Tentarix Biotherapeutics's investors include Samsara BioCapital, Versant Ventures, Gilead Sciences, Amplitude Venture Capital.
Tentarix Biotherapeutics is headquartered in San Diego, United States.
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
Tentarix Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tentarix Biotherapeutics — Funding & Investors." VCBacked, September 6, 2023, https://www.vcbacked.co/company/tentarix-biotherapeutics. Accessed July 31, 2026.
VCBacked. (2023). Tentarix Biotherapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/tentarix-biotherapeutics
{{cite web |title=Tentarix Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tentarix-biotherapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated